New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants

Penezina, Oksana; Clapham, David; Collins, Jennifer; Kovalenko, V. A.; Krueger, Neil X.; Rodriguez-Chavez, IR; Busch, Mirjam; Levin, Andrew

doi:10.1186/1742-4690-9-s2-p120

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, more than 80% of volunteers vaccinated with an adjuvanted envelope subunit protein still tested HIV-1 positive 8 years post vaccination [93]. Although Western Blot and nucleic acid tests may allow this differentiation, the development of cheaper and easier-to-run antibody-based diagnostic tests able to differentiate VISP from HIV-1 infection is actively pursued [94–96]. …”

Section: Lessons Learnt From Clinical Trialsmentioning

confidence: 99%

Novel directions in HIV-1 vaccines revealed from clinical trials

Excler

Tomaras

Russell

2013

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of review Considerable HIV-1 vaccine development efforts have been deployed over the past decade. Put into perspective, the results from efficacy trials and the identification of correlates of risk have opened large and unforeseen avenues for vaccine development. Recent findings The Thai efficacy trial, RV144, provided the first evidence that HIV-1 vaccine protection against HIV-1 acquisition could be achieved. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop inversely correlated with decreased risk of infection, while Env-specific IgA directly correlated with risk. Further clinical trials will focus on testing new envelope subunit proteins formulated with adjuvants capable of inducing higher and more durable functional antibody responses (both binding and broadly neutralizing antibodies). Moreover, vector-based vaccine regimens that can induce cell-mediated immune responses in addition to humoral responses remain a priority. Summary Future efficacy trials will focus on prevention of HIV-1 transmission in heterosexual population in Africa and men who have sex with men in Asia. The recent successes leading to novel directions in HIV-1 vaccine development are a result of collaboration and commitment among vaccine manufacturers, funders, scientists and civil society stakeholders. Sustained and broad collaborative efforts are required to advance new vaccine strategies for higher levels of efficacy.

show abstract

Section: Lessons Learnt From Clinical Trialsmentioning

confidence: 99%

Novel directions in HIV-1 vaccines revealed from clinical trials

Excler

Tomaras

Russell

2013

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

show abstract

“…The use of vaccines expressing multiple HIV proteins, in particular, envelope protein subunits, may increase the risk of vaccine-induced seropositivity (VISP) in some proportion of vaccinated individuals when using routine HIV diagnosis serological tests [ 115 ]. This has raised concerns at individual and public health levels [ 116 ] as it may seriously complicate the epidemic surveillance of a country if easy-to-perform and cheap tests are not made available [ 117 , 118 ].…”

Section: Challengesmentioning

confidence: 99%

An HIV Vaccine for South-East Asia—Opportunities and Challenges

et al. 2013

View full text Add to dashboard Cite

Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.

show abstract

“…The redesigned HIV Selectest is an antibody-capture ELISA for human IgG antibodies employing a mixture of biotinylated peptide antigens immobilized in microplate wells via a streptavidin linkage ( Fig. 1) (18). Detection of bound serum antibodies is mediated through an anti-IgG-horseradish peroxidase conjugate, whose binding is revealed colorimetrically with the soluble peroxidase substrate tetramethylbenzidine.…”

Section: Methodsmentioning

confidence: 99%